TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: High sensitivity C-reactive protein (hs-CRP), IL-6, adiponectin, leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Body mass index (BMI), bone mineral density (BMD), lipid profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abdominal Pain Intensity Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scores on anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: scores on depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects of radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Gestational age of the last required tube feed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of TNF alpha by more than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction of IL-6 by more than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction of IL-8 by more than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in retinal macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Clinical Adverse Experiences (CAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Readmission Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Bilateral BIS values at return of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory (BPI)- Short Form (SF) question 3 (BPI-SF3)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Cardiac structure and function evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Taste and smell acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor system cortical areas activation magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood trihalomethane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dopamine concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotonin concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GABA concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetylcholine concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noradrenaline concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenytoin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: referral rate for unhealthy behavior
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in type 1 and 3 excretion of vaccine poliovirus particles in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in type 1, 2 and 3 poliovirus antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with HLA-B*5701
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with idiopathic pre-capillary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tumor profile of CNS Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Retinal activity (mERG amplitude)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childbirth Self-Efficacy Inventory (CBSEI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The depression anxiety and stress scale (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Shear Wave Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vessel Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in exercise endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anthropometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborn Infant Pain Scale (NIPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Were Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTSD symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of subjects treated to target blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serum Catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Vertical component of Ground Reaction Force (VGRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyographic (EMG) parameters related to muscle activation intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Clinical Neuropathy (CCN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Disabilities of the Arm Shoulder and Hand Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 4D CT Scan Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Food cravings, state (situational)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of ordered food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of ordered food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with testosterone <=0.5ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absolute difference score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Clinical Improvement by Ordinal Scale for Clinical Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure at the most recent office visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean daily medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Development of inguinal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of oxaliplatin and etoposide
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of ifosfamide with oxaliplatin and etoposide
Endpoint domain: Adverse events/effects
Primary endpoint: PSA-progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean Percentage of Total Body Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: re-admission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in waist-to-hip ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total-to-HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in proteomic protein clusters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in trajectories of protein clusters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in levodopa-induced dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Short-term recognition memory changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attention changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Negative biopsy in the treated lobe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MMP-2 and MMP-9 serum activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of being COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with clinical deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the composite endpoint for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical change in Knee Society Score (KSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Virological efficacy at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cuff pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of bloodless field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Outdoor walking activity - CHAMPS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Outdoor walking activity - GPS data
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Outdoor walking activity - Accelerometry
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pulp sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum androgen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficacy of Ksharstra in treating Vaginal Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients With Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Patients With Assisted Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Patients With Secondary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With Serious Device or Implant Procedure-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients with CD4+ cell count above 500/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak score on Drug Liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Saint Louis University Mental Status Exam (SLUMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contextual Memory Test (CMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail Making Test part-A (TMT-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Retention in treatment program at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence in treatment program at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost of 12-month treatment program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in the Inflammatory Marker IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Plasma Soluble Markers (D-dimer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of tafluprost acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Days Covered With Medicine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Requiring Naloxone
Endpoint domain: Adverse events/effects
Primary endpoint: Driving performance as assessed by lane tracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driving performance as assessed by speed maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Rapid Polymyxin NP test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Rapid Polymyxin NP test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Pain Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician's Severity Rating of Anxiety Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of positive margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in bacterial load of total respiratory pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean difference in levels of hBD-2/IL-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Hepatitis B Surface Antigen Completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual Cancer Burden index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite of major adverse cardiac events (MACEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin levels in blood in response to Glucose Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HBA1C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: daily glucose level measurement in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of pharmaceutical consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients discharged
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mechanical and thermal pain measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory COX and Prostaglandin E2 (PGE2) gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjudicated device-oriented composite target lesion failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lab-quality results in glucose analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) of bevacizumab
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: MTD of temsirolimus
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Male fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of stopping treatment due to statin-associated myalgia
Endpoint domain: Adverse events/effects
Primary endpoint: Composite outcome measure of surgical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: maximum tolerated doses of drugs in combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall toxicity of drug combination
Endpoint domain: Adverse events/effects
Primary endpoint: preliminary antitumor activity of drug combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood stream infection
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial oxygenation (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid Content of Abdominal Adipocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eye dryness severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Tricuspid Regurgitation Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum zinc deficiency levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin D deficiency levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin B12 deficiency levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in High Sensitivity C-Reactive Protein (Hs-CRP) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Interleukin-6 (IL-6) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Global--10 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hip disability and Osteoarthritis Outcome Score, Joint Replacement (HOOS, JR)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee injury and Osteoarthritis Outcome Score, Joint Replacement (KOOS, JR)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mortality at hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Fistula thrombosis (patency failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Blood insulin change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood c-peptide change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of great SV (VO2max ≥ 80%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Better glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in lipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach Tmax in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage Change in Eczema Area and Severity Index (EASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Composite Z Score of Neuropsychological Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Antibody titers of anti-EV71 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Recurrences of Herpes Labialis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients achieving LDL-C treatment goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMI Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist to Height Ratio (WHtR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved the Ability to Stand Alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) Score at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of cholelithiasis or biliary sludge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: peripapillary vascular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: change in ovarian artery perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Alveolar bone regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ease of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dementia Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to AIDS or Death
Endpoint domain: Mortality/survival